Skip to main content
. Author manuscript; available in PMC: 2009 Jan 29.
Published in final edited form as: J Neurosci. 2008 Sep 17;28(38):9473–9485. doi: 10.1523/JNEUROSCI.1867-08.2008

Figure 6.

Figure 6

Methazolamide improves the brain weight loss and prevents the ventricular hypertrophy in R6/2 mice. At 25 weeks, groups of saline-treated and methazolamide-treated R6/2 and littermate wild-type control mice are obtained. A, The loss of brain weight in the methazolamide-treated (40 mg/kg) was significantly improved, compared with the saline-treated R6/2 mice (n = 5 for wild-type control mice; n =4 for both saline-treated and methazolamide-treated R6/2 mice). Error bars represent SD. B, Both the gross brain atrophy, ventricular enlargement (left), and neuronal atrophy (right) present in saline-treated R6/2 mice was significantly reduced by methazolamide administration. Scale bars, 2 mm (for gross brain), 100 μm (for striatal neurons). Neuropathological data were compared by ANOVA or repeated measures of ANOVA and by nonpaired Student’s t test (Statview). *p <0.05. Data is representative from n =5 for wild-type control mice, n =4 for both saline-treated and methazolamide-treated R6/2 mice.